Related Experiment Video
Updated: Apr 6, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Chemotherapy in Prostate Cancer.
1Yale Comprehensive Cancer Center, 333 Cedar Street, New Haven, CT, 06520, USA, michael.hurwitz@yale.edu.
Chemotherapy prolongs life for metastatic castration-resistant prostate cancer (mCRPC). Recent advances include adding chemotherapy to hormonal therapy for castration-sensitive disease, with ongoing research into new treatments and resistance mechanisms.
Area of Science:
- Oncology
- Urology
- Pharmacology
Background:
- Chemotherapy has been a cornerstone in extending survival for metastatic castration-resistant prostate cancer (mCRPC) for about ten years.
- Limited life-prolonging agents (docetaxel, cabazitaxel) have been approved for mCRPC.
- Recent guidelines now recommend chemotherapy combined with primary hormonal therapy for high-volume castration-sensitive metastatic prostate cancer.
Purpose of the Study:
- To review current chemotherapy options for prostate cancer.
- To discuss established and emerging mechanisms of chemotherapy resistance.
- To highlight ongoing clinical trials investigating novel chemotherapeutics and combination strategies.
Main Methods:
- Literature review of current prostate cancer chemotherapies.
- Analysis of mechanisms of resistance to chemotherapy.
- Overview of ongoing clinical studies and novel agents.
Main Results:
- Docetaxel and cabazitaxel remain key agents in mCRPC treatment.
- Combination chemotherapy with hormonal therapy is now standard for high-volume castration-sensitive disease.
- Research is actively exploring new chemotherapeutic agents and strategies to overcome resistance.
Conclusions:
- Chemotherapy plays a vital role in managing advanced prostate cancer.
- Understanding and overcoming resistance mechanisms is crucial for improving patient outcomes.
- Ongoing research promises to expand the therapeutic armamentarium for prostate cancer patients.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

